An observational study in Stable Angina, Unstable Angina and ACS - Acute Coronary Syndrome, sponsored by CeloNova BioSciences, Inc.. Completed at 18 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-07.
Sponsored by CeloNova BioSciences, Inc. · Observational
A multi-center, prospective, consecutive enrolled, observational registry. The population being studied includes all patients undergoing treatment of "de novo" lesions in native coronary vessels, saphenous vein graft and/or arterial bypass conduits with the COBRA PzF coronary stent system. The registry will primarily assess the rate of MACE (cardiac death, myocardial infarction and clinically driven target lesion revascularization.
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's enrollment of 1,027 is above the median of 500 across 983 observational studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →CeloNova BioSciences, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients undergoing treatment of "de novo" lesions in native coronary vessels, saphenous vein graft and/or arterial bypass conduits with the COBRA PzF coronary stent system
Patient has given oral consent to participate in the registry Patient is implanted with a COBRA PzF stent Target lesion(s) is/are "de novo"
Exclusion Criteria:
Pregnancy Age \<18 years Refusal or inability to give oral consent
COBRA PzF Coronary Stent System
MACE
Composite clinical endpoint of cardiac death, myocardial infarction, and clinically driven target lesion revascularization
Time frame: 12 months
Stent thrombosis
Stent thrombosis (according to ARC definition)
Time frame: 12 months
TVR and TLR
Target vessel and lesion revascularization
Time frame: 12 months
DAPT
Mean length of dual antiplatelet therapy
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CeloNova BioSciences, Inc.